Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Epilepsy (Dec 2018)

Posted by Matt Breese on Dec 28, 2018

Find me on:

According to our recent payer coverage analysis for epilepsy treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for epilepsy treatments shows that almost 29% of the covered lives under the pharmacy benefit in commercial formularies have utilization management restrictions on epilepsy medications.

MMIT-Reality Check-Epilepsy_4Q2018Data snapshot as of Q4 2018

Trends: Epidiolex, the first FDA-approved treatment that contains a purified drug substance derived from marijuana, is now available in the U.S. Via AIS Health.

To read the full Reality Check on Epilepsy treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing